肺癌化疗中铂类耐药的研究进展  

Research Advances in Resistance to Platinum-based Chemotherapy in Lung Cancer

作　　者：张亚娟[1,2] 常德[1] 张健鹏[1] 

机构地区：[1]中国人民武装警察部队总医院呼吸内科,北京100039 [2]锦州医科大学临床医学系,辽宁锦州121001

出　　处：《中国医学科学院学报》2017年第1期150-155,共6页Acta Academiae Medicinae Sinicae

基　　金：国家自然科学基金(81402471);北京市科技新星计划(2017008);武警总医院培育项目(WZ201406)~~

摘　　要：铂类化疗药物是治疗多种恶性肿瘤的基础用药,在非小细胞肺癌中,铂类联合其他药物仍是治疗的主要方案,早期效果显著。随着疗程进展,肿瘤细胞对化疗药物产生耐药是影响疗效和预后的重要因素,其耐药机制复杂,如膜蛋白表达异常、DNA修复功能增强、凋亡调控机制异常、细胞解毒功能增强等。本文总结了肺癌细胞铂类耐药的一些主要机制,以期帮助开发新的靶点类似物或抑制剂,与铂类药物联合使用提高疗效。Platinum-based chemotherapy is the the cornerstone of treatment of many cancers. Combinations of platinum drugs with other agents are still the mainstream therapies for non-small cell lung cancer, showing significant effectiveness in an early phase. Along with the treatment, the tumor cells can become resistant to chemotherapy drugs, which affect the efficacy and prognosis. The mechanisms of drug resistance are complicated, including abnormal expressions of membrane proteins, enhanced DNA repair functions, abnormal regulation mechanisms of apoptosis, and enhanced cellular detoxification function. In this article we summarize some of the main mechanisms of platinum resistance in lung cancer cells, with an attempt to identify new potential target analogues or inhibitors and improve the efficacies of the combined use of platinum-based drugs.

关 键 词：肺癌化疗 铂类化疗药物 耐药机制 

分 类 号：R73[医药卫生—肿瘤]